SG11201504579QA - Human milk oligosaccharides to ameliorate symptoms of stress - Google Patents

Human milk oligosaccharides to ameliorate symptoms of stress

Info

Publication number
SG11201504579QA
SG11201504579QA SG11201504579QA SG11201504579QA SG11201504579QA SG 11201504579Q A SG11201504579Q A SG 11201504579QA SG 11201504579Q A SG11201504579Q A SG 11201504579QA SG 11201504579Q A SG11201504579Q A SG 11201504579QA SG 11201504579Q A SG11201504579Q A SG 11201504579QA
Authority
SG
Singapore
Prior art keywords
stress
human milk
ameliorate symptoms
milk oligosaccharides
oligosaccharides
Prior art date
Application number
SG11201504579QA
Inventor
Jomay Chow
Matthew Panasevich
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49943540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504579Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SG11201504579QA publication Critical patent/SG11201504579QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
SG11201504579QA 2012-12-18 2013-12-18 Human milk oligosaccharides to ameliorate symptoms of stress SG11201504579QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738491P 2012-12-18 2012-12-18
PCT/US2013/076026 WO2014100126A1 (en) 2012-12-18 2013-12-18 Human milk oligosaccharides to ameliorate symptoms of stress

Publications (1)

Publication Number Publication Date
SG11201504579QA true SG11201504579QA (en) 2015-07-30

Family

ID=49943540

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504579QA SG11201504579QA (en) 2012-12-18 2013-12-18 Human milk oligosaccharides to ameliorate symptoms of stress

Country Status (15)

Country Link
US (1) US10779550B2 (en)
EP (1) EP2934189B1 (en)
CN (1) CN104822279B (en)
BR (1) BR112015014420A2 (en)
CA (1) CA2893217C (en)
DK (1) DK2934189T3 (en)
ES (1) ES2763958T3 (en)
HK (1) HK1217082A1 (en)
IL (1) IL239107A0 (en)
MX (1) MX2015007933A (en)
MY (1) MY187609A (en)
PH (1) PH12015501309A1 (en)
SG (1) SG11201504579QA (en)
TW (1) TW201438719A (en)
WO (1) WO2014100126A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014497A1 (en) * 2014-07-21 2016-01-28 Abbott Laboratories Nutritional powder pods containing nutritional powders with volume flowability properties
EP3171743A1 (en) * 2014-07-21 2017-05-31 Abbott Laboratories Nutritional powder pods comprising dry blended carbohydrates
EP3171713A1 (en) * 2014-07-21 2017-05-31 Abbott Laboratories Nutritional powder with specific antioxidants
CN106535721A (en) * 2014-07-21 2017-03-22 雅培制药有限公司 Nutritional powder pods and related methods
US20170203914A1 (en) * 2014-07-21 2017-07-20 Abbott Laboratories Nutritional powder pod with extruded nutritional powder
EP3171740A1 (en) * 2014-07-21 2017-05-31 Abbott Laboratories Nutrient delivery system comprising nutritional powder comprising phospholipids to improve wettability
WO2016014473A1 (en) * 2014-07-21 2016-01-28 Abbott Laboratories Nutrient delivery system with human milk oligosaccharides
KR20170072879A (en) * 2014-10-29 2017-06-27 네스텍 소시에테아노님 Use of l. reuteri for recovery of microbiota dysbiosis in early life
US10780103B2 (en) 2015-10-28 2020-09-22 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
EP3368046B1 (en) * 2015-10-28 2022-07-27 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
CN108472305A (en) * 2016-01-13 2018-08-31 Benebiosis株式会社 Make the increased composition of expression of peroxisome proliferation-activated receptors co-activation factor 1- α
WO2017215722A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic composition comprising hmo and method for modulating emotion and mood disorders
RU2019105567A (en) 2016-07-28 2020-08-28 Фонтерра Ко-Оперэйтив Груп Лимитед DAIRY PRODUCT AND METHOD
RU2019141949A (en) * 2017-05-24 2021-06-17 Сосьете Де Продюи Нестле С.А. NUTRIENT COMPOSITION FOR USE IN INCREASING ATTENTION AND / OR REDUCING IMPULSE
US11541067B2 (en) 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing detrimental proteolytic metabolites
EP3450443A1 (en) * 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides
CA3081496A1 (en) * 2017-11-02 2019-05-09 Glycom A/S Mixture of hmos for reducing or preventing fatigue
EP3716984B1 (en) * 2017-11-30 2024-03-20 Glycom A/S Mixture of hmos for treating wheat sensitivity
WO2019110800A1 (en) * 2017-12-08 2019-06-13 Jennewein Biotechnologie Gmbh Spray-dried mixture of human milk oligosacchrides
EP3743078A4 (en) * 2017-12-22 2022-01-19 Glycom A/S COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION
EP3749328A1 (en) * 2018-02-09 2020-12-16 N.V. Nutricia Fermented formula with non-digestible oligosaccharides
EP3546060A1 (en) * 2018-03-27 2019-10-02 DuPont Nutrition Biosciences ApS Process for spray drying fucosyllactose solutions and related product compositions
GB2573539A (en) * 2018-05-09 2019-11-13 Mjn Us Holdings Llc Wellbeing supplement for postpartum maternal nutrition
CN109355231A (en) * 2018-11-28 2019-02-19 江苏微康生物科技有限公司 The preparation method of organic probiotics bacterial powder
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
ES1240969Y (en) * 2019-09-18 2020-07-30 Jennewein Biotechnologie Gmbh CEREAL COMPOSITIONS CONTAINING OLIGOSACCHARIDS FROM HUMAN MILK
KR102241938B1 (en) * 2020-09-14 2021-04-20 (주)에이피테크놀로지 Food composition for improvement of cerebral cardiovascular disease with 2'-fucosyllactose
EP4186512A1 (en) 2020-09-14 2023-05-31 Advanced Protein Technologies Corp. Food composition for alleviating or treating cardio-cerebrovascular disease, and pharmaceutical composition for preventing or treating cardio-cerebrovascular disease, comprising 2'-fucosyllactose
WO2022106416A1 (en) * 2020-11-23 2022-05-27 Dsm Ip Assets B.V. Edible decorative element comprising human milk oligosacchrides
WO2023237306A1 (en) * 2022-06-09 2023-12-14 Dsm Ip Assets B.V. Nutritional composition comprising gos and hmos

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9807443A (en) 1997-02-21 2000-04-25 Abbott Lab Processes for reducing the incidence of necrotic enterocolitis in a child and for the production of an enteral formula, and, improved enteral formulas containing arachidonic acid and docosahexaenoic acid and suitable for feeding children.
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
CA2530437C (en) * 2003-06-23 2011-11-15 Nestec S.A. Nutritional formula for optimal gut barrier function
ATE361101T1 (en) 2004-08-24 2007-05-15 Nutricia Nv FOOD COMPOSITION CONTAINING INDIGESTIBLE OLIGOSACCHARIDES
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
EP3338784B1 (en) * 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
WO2012092160A2 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US9539269B2 (en) * 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
NZ612504A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals

Also Published As

Publication number Publication date
HK1217082A1 (en) 2016-12-23
CN104822279A (en) 2015-08-05
MY187609A (en) 2021-10-04
CN104822279B (en) 2020-09-11
CA2893217C (en) 2017-11-28
BR112015014420A2 (en) 2017-07-11
US10779550B2 (en) 2020-09-22
EP2934189B1 (en) 2019-11-06
US20150320778A1 (en) 2015-11-12
IL239107A0 (en) 2015-07-30
TW201438719A (en) 2014-10-16
MX2015007933A (en) 2015-10-09
CA2893217A1 (en) 2014-06-26
EP2934189A1 (en) 2015-10-28
ES2763958T3 (en) 2020-06-01
WO2014100126A1 (en) 2014-06-26
DK2934189T3 (en) 2019-11-25
PH12015501309A1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
HK1217082A1 (en) Human milk oligosaccharides to ameliorate symptoms of stress
HK1211844A1 (en) Treatment of pulmonary disease
HK1201452A1 (en) Methods of reducing risk of cardiovascular disease
EP2932375A4 (en) Matching opportunity to context
EP2872184A4 (en) Use of cart19 to deplete normal b cells to induce tolerance
EP2805287A4 (en) Use of human input recognition to prevent contamination
ZA201406702B (en) No bake granola product and methods of preparation
PT2539136T (en) Methods of connecting
EP2817275A4 (en) Conversion of lipids
HK1211213A1 (en) Treatment of diseases involving mucin
GB201311220D0 (en) Improved structure of shoe
EP2832768A4 (en) Preparation method of polyimide
HK1204573A1 (en) Treatment of inflammatory skin disorders
IL236312A0 (en) Preparation of 18f-fluciclovine
HK1208890A1 (en) Noninvasive detection of fetal health status
EP2773262A4 (en) Evaluation of cardiac structure
EP2805168A4 (en) Compositions and methods relating to lyme disease
EP2904119A4 (en) Methods relating to dna-sensing pathway related conditions
GB201312378D0 (en) Structure of shoe
AP2015008378A0 (en) Improvements relating to buoyancy-supported risers
PL2811845T3 (en) Maternal supplement to enhance immune system of an infant
SI2883057T1 (en) Diagnostic of heart failure
HUP1100272A2 (en) Pharmaceutical use of silicic acid
GB201219092D0 (en) Treatment of cardiovascular disease
GB201016181D0 (en) Milk to go